For descriptive purposes, continuous variables were summarized as arithmetic mean and standard deviation (SD), whereas categorical variables were expressed as frequencies and proportions. The Pearson's chi-square and Wilcoxon tests were used for assessing the statistical significance of clinical parameters. The Kaplan-Meier method used to estimate survival curves of individual variables using the Cochran-Mantel-Haenszel log-rank test.Results: The significant factors for gender comparisons were age (p ¼ 0.0004, Welch's t test; p <0.0001), and percentage of estrogen receptors (p ¼ 0.0030, Welch's t test; p ¼ 0.0002). The most common clinical stages in men (n ¼ 30) were IIIB (23.3%), IIB (20%) and IIA (16.6%), while in women (n ¼ 2999) the most frequent stages were I (21.2%), IIA (21.3%) and IIIA (15.1%). The tumor grade (p ¼ 0.1792), lymphovascular permeation (p ¼ 0.9115, chi-square test), the proportions of patients treated with adjuvant chemotherapy (p ¼ 0.1193, Pearson's chi-square test) were similar in both groups. Median progression-free survival was 24.8 months (95% CI: 12.5 e 59.35) in males and in females 54.04 months (95% CI: 40.97 e 68.99) (p ¼ 0.0026), and median overall survival was 35.38 months (95% CI: 20.06 e 58.88) in males and in females 60.02 months (95% CI: 48 e 75.93) (p ¼ 0.0001); the average value of time to progression and overall survival is almost double for women compared to men.Conclusions: In our study, male breast cancer were diagnosed in more proportion locally advanced clinical stages compared to the distribution of clinical stages in women who were diagnosed in earlier stages, the disease-free survival and overall survival were lower in men than in the female group. Male breast cancer patients have a worse survival outcome than female patients. Male breast cancer patients have lower survival compared to the female patients.Legal entity responsible for the study: The authors.

No abstract

No abstract